 |
 |
Published
Patents |
Title |
Patent
Number |
| Polynucleotide vaccine |
WO03/000894 |
| Vaccine comprising polynucleotide |
WO2004/058299 |
| Method and composition
for regulating the activity of regulatory T cells |
WO2004/024174 |
|
|
Important
References |
|
- Nagata, Y., Furugen, R., Hiasa , A., Ikeda,
H., Ohta , N., Furukawa, K., Nakamura, H., Furukawa, K.,
Kanematsu, T. and Shiku, H. : Peptides derived from
a wild type murine proto- oncogene c-erB-2/HER2/neu can
induce CTL and tumor suppression in syngeneic hosts. J.
Immunol . 159: 1336-1343, 1997.
- Ikeda, H., Ohta, N., Furukawa, K., Miyazaki,
H., Wang, L., Kuribayashi, K., Old, L.J. and Shiku,
H. : Mutated mitogen-activated protein kinase: a tumor
rejection antigen of mouse sarcoma. Proc. Natl. Acad.
Sci. USA 94: 6375-6379, 1997.
- Okugawa, T., Ikuta, Y., Takahashi, Y.,
Obata, H., Tanida, K., Watanabe, M., Imai, S., Furugen,
R., Nagata, Y., Toyoda, N. and Shiku, H. : A novel
human HER2-derived peptide homologous to the mouse K(d)
-restricted tumor rejection antigen can induce HLA-A24
restricted cytotoxic T lymphocytes in ovarian cancer patients
and healthy individuals. Eur. J. Immunol. 30 : 3338-3346,
2000.
- Nishikawa, H., Tanida, K., Ikeda, H., Sakakura,
M., Miyahara, Y., Aota, T., Mukai, K., Watanabe, M., Kuribayashi,
K., Old, LJ. and Shiku, H. : Role of SEREX-defined
immunogenic wild-type cellular molecules in the development
of tumor specific immunity. Proc. Natl. Acad. Sci. USA.
98:14571-14576, 2001.
- Ikuta,Y.,Katayama,N.,Wang,L.,Okugawa,T.,Takahashi,Y.,Schmitt,M.,
Gu,X., Watanabe,M., Akiyoshi,K., Nakamura,H., Kuribayashi,K.,
Sunamoto,J. and Shiku,H. :Presentation of a major
histocompatibility complex class 1-binding peptide by
monocyte-derived dendritic cells incorporating hydrophobized
polysaccharide-truncated HER2 protein complex: implications
for a polyvalent immuno-cell therapy. Blood 99:3717-3724,
2002.
- Mukai, K., Yasutomi, Y., Watanabe, M., Kenjo,
A., Aota, T., Wang, L., Nishikawa, H., Ishihara, M., Fujita,
T., Kuribayashi, K. and Shiku, H.: HER2 peptide-specific
CD8(+) T cells are proportionally detectable long after
multiple DNA vaccinations. Gene Ther. 9:879-888, 2002.
- Nishikawa, H., Kato, T., Tanida, K., Hiasa,
A., Tawara, I., Ikeda, H., Ikarashi, Y., Wakasugi, H., Kronenberg,
M., Nakayama, T., Taniguchi, M., Kuribayashi, K., Old, L.J.,
and Shiku, H.: CD4+ CD25+ T
cells responding to serologically defined autoantigens suppress
antitumor immune response. Proc. Natl. Acad. Sci. USA. 100:10902-10906,
2003.
|
|
|
|
